Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

SALT LAKE CITY, March 16, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the Sidoti Small Cap Conference, to be held March 18-19, 2026. Mr. Fife and Mr.

LifeVantage Corporation (LFVN) Q2 2026 Earnings Call Transcript

Lifevantage (LFVN) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.22 per share a year ago.

SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid March 16, 2026 to all stockholders of record at the close of business on March 2, 2026.

SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve Fife, President, Chief Executive Officer and a member of the Board of Directors (the “Board”), has decided to retire in April, 2026. Fife will continue in his role as President and Chief Executive Officer during the transition period to ensure business continuity through his retirement date. The Board is conducting an extensive executive search and anticipates announcing the new CEO in the coming months.

SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025. Second Quarter Fiscal 2026 Summary*: Revenue was $48.9 million, a decrease of 27.8% from the prior year period.

Boosted sales guidance in Life360's (LIF) earnings offered a more than 20% rally for a stock that was initially down more than 50% from its 2025 high. George Tsilis explains how the company gained traction in the U.S. and abroad to back its new financial trajectory.